VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
2.820
+0.090 (3.30%)
Nov 20, 2024, 4:00 PM EST - Market closed
VYNE Therapeutics Employees
VYNE Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 2 or -16.67% compared to the previous year.
Employees
10
Change (1Y)
-2
Growth (1Y)
-16.67%
Revenue / Employee
$49,300
Profits / Employee
-$3,414,900
Market Cap
41.60M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
NeueHealth | 1,252 |
RAPT Therapeutics | 131 |
BioLineRx | 79 |
Rallybio | 43 |
LAVA Therapeutics | 37 |
CERo Therapeutics Holdings | 9 |
Intensity Therapeutics | 7 |
Nexalin Technology | 6 |
VYNE News
- 2 months ago - VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewsWire
- 5 months ago - VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 - GlobeNewsWire
- 7 months ago - VYNE Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 8 months ago - VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire